Lost in transmission--FDA drug information that never reaches clinicians.
about
Long term effectiveness on prescribing of two multifaceted educational interventions: results of two large scale randomized cluster trialsInformation on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.Assessing general side effects in clinical trials: reference data from the general population.Different black box warning labeling for same-class drugs.Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.The Drug Facts Box: Improving the communication of prescription drug informationA plea for a more epidemiological and patient-oriented pharmacovigilance.Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications.Toward a jurisprudence of drug regulation.Eszopiclone-induced Parasomnia with Suicide Attempt: A Case Report.A cross-national comparison of 17 countries' insulin glargine drug labels.Getting to better prescription drug information.Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment.Better public communication of benefits and harms of colorectal interventions.A concise display of multiple end points for benefit-risk assessment.Speaking the same language? International variations in the safety information accompanying top-selling prescription drugs.Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence
P2860
Q28543892-F9599A42-42BE-4494-B271-6B81BB881F59Q30487681-4B58E7EE-6F19-49BE-BC28-72CB965BDE5AQ33856964-B9FAE994-C581-4829-A831-258C824E8741Q35007039-8ECEF71F-2ECA-407F-888E-958ADC279ABBQ36174876-99CD88CF-8C68-46F6-B451-19BF8E20A3AAQ37117584-E972ED1B-BAA8-4C8B-811C-750E89704481Q37902956-575BC704-E297-4280-9C53-666A1F583F5CQ39105190-38E590C7-2376-41C9-B129-95A575BFF555Q39198481-EA99B9EE-B5FE-410E-9717-03979B99BD4DQ41896124-9742EC45-B46A-4510-8E00-824158790F3DQ42195355-FDDADB3B-F376-49AD-868D-D7D28F1E7043Q42364946-99393307-DA74-4900-9A39-5F599FF296A4Q44670585-6E7404E9-2FCE-419D-AE9B-0E2F6454CE6BQ45240145-9B9A0553-DDAA-459C-8A87-7E0968027089Q45278471-3AFDC76A-D804-47ED-B9D0-640558F03EA4Q45347829-173E32B5-96A1-4388-B7CE-3BB2166DB98BQ58720703-466FE10C-37CD-4EA4-BB41-80E6121A8679
P2860
Lost in transmission--FDA drug information that never reaches clinicians.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lost in transmission--FDA drug information that never reaches clinicians.
@ast
Lost in transmission--FDA drug information that never reaches clinicians.
@en
type
label
Lost in transmission--FDA drug information that never reaches clinicians.
@ast
Lost in transmission--FDA drug information that never reaches clinicians.
@en
prefLabel
Lost in transmission--FDA drug information that never reaches clinicians.
@ast
Lost in transmission--FDA drug information that never reaches clinicians.
@en
P356
P1476
Lost in transmission--FDA drug information that never reaches clinicians.
@en
P2093
Lisa M Schwartz
Steven Woloshin
P304
P356
10.1056/NEJMP0907708
P407
P577
2009-10-21T00:00:00Z